A new treatment regimen for drug-resistant TB

India is getting ready to roll out BPaL (bedaquiline, pretomanid, and linezolid) regimen for all multi/extensively drug-resistant tuberculosis patients.

  • This is a significant move in the country’s battle against with the new regime indicating good results in countries including Pakistan, South Africa, Ukraine, etc.
  • The continuing spread of drug-resistant tuberculosis (TB) is one of the most urgent and difficult challenges facing global TB control.
Multidrug-resistant (MDR) TB: Patients who are infected with strains resistant to isoniazid and rifampicin, called multidrug-resistant (MDR) TB, are practically incurable by standard first-line treatment. 

Extensively drug-resistant (XDR) TB: It  refers to MDR-TB strains that are resistant to fluoroquinolones and second-line injectable drugs. 

Causes:

The main causes of the spread of resistant TB are weak medical systems, amplification of resistance patterns through incorrect treatment, and transmission in communities and facilities. 

What is BPaL?

  • BPaL is a new all-oral combination of drugs consisting of Bedaquiline (B), Pretomanid (Pa) and Linezolid (L). 
  • The new regimen is also expected to be more cost-effective, reducing treatment costs significantly.

Enroll now for UPSC Online Classes

Significance

  • Cost Effective: “After the availability of generic bedaquiline cost to TB programmes has fallen – (BPaLM price is US$426 (US$130 bedaquiline, US$238 pretomanid, US$31 linezolid and US$27 moxifloxacin). 
  • Enhance Treatment Outcomes: The regimen shortens treatment duration from 18-24 months to about six months and simplifies the process to three daily tablets, compared to the previous regimen of 14 drugs.
  • Increase Adherences treatment:  A shorter regimen, such as BPaL, which is all oral and requires lesser doses per day, will make it easier for a patient to adhere to and complete treatments,

Impact on Treatment

  • Currently, India’s success rate for MDR/RR-TB is 56%, and 48% for XDR-TB. 
  • The BPaL regimen, endorsed by the WHO, aims to improve these rates by offering a shorter, less toxic treatment.
  •  According to a recent study, the BPaL/BPaLM regimens have been proven to be more effective, affordable, and less burdensome for patients.

Elimination Strategy

Although patients harbouring MDR and XDR strains present a formidable challenge for treatment, cure is often possible with early identification of resistance and use of a properly designed regimen

  • Scaling up NAAT (diagnosis) coverage will be an essential element of the strategy.
  • Community-based programs can improve treatment outcomes by allowing patients to be treated in their homes and addressing socioeconomic barriers to adherence.

Check Out UPSC NCERT Textbooks From PW Store

A nucleic acid amplification test, or NAAT, for tuberculosis (TB) is a molecular test used to detect the DNA (deoxyribonucleic acid) of Mycobacterium tuberculosis complex (MTBC) in a sputum or other respiratory sample.

 

Must Read
UPSC Daily Editorials UPSC Daily Current Affairs
Check Out UPSC NCERT Textbooks From PW Store Check Out UPSC Modules From PW Store 
Check Out Previous Years Papers From PW Store UPSC Test Series 2024
Daily Current Affairs Quiz Daily Main Answer Writing
Check Out UPSC CSE Books From PW Store

 

To get PDF version, Please click on "Print PDF" button.

Need help preparing for UPSC or State PSCs?

Connect with our experts to get free counselling & start preparing

THE MOST
LEARNING PLATFORM

Learn From India's Best Faculty

      
Quick Revise Now !
AVAILABLE FOR DOWNLOAD SOON
UDAAN PRELIMS WALLAH
Comprehensive coverage with a concise format
Integration of PYQ within the booklet
Designed as per recent trends of Prelims questions
हिंदी में भी उपलब्ध
Quick Revise Now !
UDAAN PRELIMS WALLAH
Comprehensive coverage with a concise format
Integration of PYQ within the booklet
Designed as per recent trends of Prelims questions
हिंदी में भी उपलब्ध

<div class="new-fform">







    </div>

    Subscribe our Newsletter
    Sign up now for our exclusive newsletter and be the first to know about our latest Initiatives, Quality Content, and much more.
    *Promise! We won't spam you.
    Yes! I want to Subscribe.